The near-equal split of shared versus specific variants may suggest that while broad immune-regulatory mechanisms (for example, NF-κB and JAK-STAT pathways) are common therapeutic targets, tailored interventions addressing subtype-unique variants (e.g., autophagy modulators in CD) may improve precision medicine strategies. This evidence concerns the gene NFKB1 and Cowden disease.